| Objective A systematic review was conducted to evaluate the clinical efficacy of Kanglaite injection combined with the first-line platinum-containing chemotherapy (the NP regimen: paclitaxel plus cisplatin) compared to the NP regimen for the treatment of advanced non-small cell lung cancer (NSCLC). Methods The study followed the methods of searching Chinese databases (CNKI, VIP, Wanfang, and Sinomed) and English databases (PubMed, Embase, and Cochrane Library) for randomized controlled trials (RCTs) on Kanglaite Injection in the treatment of advanced NSCLC. The selected literature was screened, relevant data were extracted, and the risk of bias was evaluated before conducting a meta-analysis using RevMan 5.4. Results A total of 19 studies were included, and the analysis showed that KLT injection combined with NP chemotherapy could improve the disease control rate (DCR) [RR=1.12, 95%CI (1.04, 1.20), P<0.05], improve the functional status score (KPS) [RR=1.67, 95%CI (1.43, 1.94), P<0.05], enhance immune function, increase CD3+ [MD=3.65, 95%CI (0.47, 12.10), P=0.03], CD4+ [MD=3.65, 95%CI (0.66, 6.64), P=0.02], and CD4+/CD8+ [MD=0.34, 95%CI (0.27, 0.40), P<0.05] levels, and reduce the incidence of chemotherapy-related adverse reactions such as leukopenia [RR=0.65, 95%CI (0.49, 0.87), P<0.05], thrombocytopenia [RR=0.69, 95%CI (0.58, 0.81), P<0.05], and anemia [RR=0.58, 95%CI (0.43, 0.79), P<0.05], and can reduce the incidence of gastrointestinal reactions [RR=0.61, 95%CI (0.46, 0.80), P<0.05]. Except for the comparison of CD8+ levels, all results were statistically significant.Conclusion Kanglaite injection combined with the first-line platinum-containing chemotherapy (NP regimen) can improve DCR and immune function of patients with advanced NSCLC, improve patients’ survival quality, and reduce the incidence of chemotherapy-related adverse reactions. |
